Elmquist, William F.

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology

Barrier Structure and Function StudiesGlioma Diagnosis and Treatment

Cited by 746

Distribution kinetics of a micelle-forming block copolymer Pluronic P85

Batrakova, E. V., Li, S., Li, Y., Alakhov, V. Y., Elmquist, W. F., & Kabanov, A. V. (2004) · Journal of Controlled Release

Drug Transport and Resistance MechanismsNanoparticle-Based Drug Delivery

Cited by 121

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentBarrier Structure and Function Studies

Cited by 39

How much is enough? Impact of efflux transporters on drug delivery leading to efficacy in the treatment of brain tumors

Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023) · Pharmaceutical Research

Drug Transport and Resistance MechanismsBarrier Structure and Function Studies

Cited by 19

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 8

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 2

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 0